These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37339580)

  • 1. Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma.
    Song Z; Wu W; Wei W; Xiao W; Lei M; Cai KQ; Huang DW; Jeong S; Zhang JP; Wang H; Kadin ME; Waldmann TA; Staudt LM; Nakagawa M; Yang Y
    Blood; 2023 Oct; 142(15):1297-1311. PubMed ID: 37339580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
    Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.
    Li Y; Wang K; Song N; Hou K; Che X; Zhou Y; Liu Y; Zhang J
    Invest New Drugs; 2020 Jun; 38(3):599-609. PubMed ID: 31177400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.
    Dien Bard J; Gelebart P; Anand M; Zak Z; Hegazy SA; Amin HM; Lai R
    Am J Pathol; 2009 Aug; 175(2):825-34. PubMed ID: 19608866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
    BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
    Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G;
    Oncotarget; 2016 Nov; 7(48):79637-79653. PubMed ID: 27793034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
    Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
    J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK/STAT3 Signaling Activation Related to Distinct Clinicopathologic Features in Systemic ALK - Anaplastic Large Cell Lymphomas : New Insights into Their Heterogeneity.
    Wang JC; Zhong LH; Lin WQ; Zhang WF; Xi YF; Liu YP; Zhu Q; Liu W; Zhu WF; Chen YP; Chen G
    Am J Surg Pathol; 2023 Jan; 47(1):55-64. PubMed ID: 36315833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK-positive (2p23 rearranged) anaplastic large cell lymphoma with localization to the skin in a pediatric patient.
    Pulitzer M; Ogunrinade O; Lin O; Steinherz P
    J Cutan Pathol; 2015 Mar; 42(3):182-187. PubMed ID: 25404214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and characterization of TK-ALCL1: a novel NPM-ALK-positive anaplastic large-cell lymphoma cell line.
    Sungwan P; Panaampon J; Kariya R; Kamio S; Nakagawa R; Hirozane T; Ogura Y; Abe M; Hirabayashi K; Fujiwara Y; Kikuta K; Okada S
    Hum Cell; 2024 Jul; 37(4):1215-1225. PubMed ID: 38755432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.
    Querfeld C; Khan I; Mahon B; Nelson BP; Rosen ST; Evens AM
    Oncology (Williston Park); 2010 Jun; 24(7):574-87. PubMed ID: 20669794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to Diagnose Anaplastic Large Cell Lymphoma on Cytological Samples? A Series with Emphasis on Diagnostic Clue and Pitfalls.
    Montella M; Lucà S; Ronchi A; Marino FZ; Caputo A; Sica A; Zeppa P; Franco R; Cozzolino I
    Acta Cytol; 2023; 67(3):230-239. PubMed ID: 36634640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
    Merkel O; Hamacher F; Laimer D; Sifft E; Trajanoski Z; Scheideler M; Egger G; Hassler MR; Thallinger C; Schmatz A; Turner SD; Greil R; Kenner L
    Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16228-33. PubMed ID: 20805506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells.
    Babin L; Darchen A; Robert E; Aid Z; Borry R; Soudais C; Piganeau M; De Cian A; Giovannangeli C; Bawa O; Rigaud C; Scoazec JY; Couronné L; Veleanu L; Cieslak A; Asnafi V; Sibon D; Lamant L; Meggetto F; Mercher T; Brunet E
    Mol Cancer; 2022 Mar; 21(1):65. PubMed ID: 35246138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALCL by any other name: the many facets of anaplastic large cell lymphoma.
    Irshaid L; Xu ML
    Pathology; 2020 Jan; 52(1):100-110. PubMed ID: 31706671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
    Subbiah V; Kuravi S; Ganguly S; Welch DR; Vivian CJ; Mushtaq MU; Hegde A; Iyer S; Behrang A; Ali SM; Madison RW; Venstrom JM; Jensen RA; McGuirk JP; Amin HM; Balusu R
    ESMO Open; 2021 Aug; 6(4):100172. PubMed ID: 34242968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.
    Stein H; Foss HD; Dürkop H; Marafioti T; Delsol G; Pulford K; Pileri S; Falini B
    Blood; 2000 Dec; 96(12):3681-95. PubMed ID: 11090048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.
    Schmidt J; Bonzheim I; Steinhilber J; Montes-Mojarro IA; Ortiz-Hidalgo C; Klapper W; Fend F; Quintanilla-Martínez L
    Lab Invest; 2017 Sep; 97(9):1095-1102. PubMed ID: 28581487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT; Zhao C; Zhang Q; Wasik MA
    Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma.
    Bard JD; Gelebart P; Anand M; Amin HM; Lai R
    Leukemia; 2008 Aug; 22(8):1595-603. PubMed ID: 18509351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.